Radium-223 in Biochemically Recurrent Prostate Cancer

NCT04206319 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

NIH

Sponsor class

Conditions

Biochemical Recurrent Prostate Cancer

Interventions

DRUG: Radium-223
DRUG: 18F Sodium Fluoride

Sponsor

National Cancer Institute (NCI)